Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Alexza Pharmaceuticals Drops on Rejection of Schizophrenia Drug


Alexza says the FDA won't approve the drug Adasuve after citing manufacturing problems at a company plant. In premarket trading Friday, the stock fell 38%

Alexza Pharmaceuticals' (ALXA) shares are dropping after the company's experimental inhaled drug for schizophrenia was rejected by the Food and Drug Administration. Alexza says the FDA won't approve the drug after citing manufacturing problems at a company plant in Mountain View, California. The drug is designed to treat agitation in adults with schizophrenia or bipolar disorder. In premarket trading Friday, the stock fell 38% to $0.38 per share.

The drug, Adasuve, was rejected in 2010 on concerns about respiratory side effects. On the company's next attempt for approval, a panel of FDA expert advisers voted 9-8 in December to clear the drug for sale on the condition that the company develop a plan to mitigate risks with taking the drug. There's a concern about respiratory side effects going undetected in psychiatric patients. Alexza says it will talk to the FDA about both the manufacturing problems and what's known as a risk evaluation and mitigation strategy for the drug.

(See Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May [UPDATE].)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos